Full Year 2024 AddLife AB Earnings Call Transcript
Key Points
- AddLife AB (FRA:1AD1) reported a strong finish to 2024 with an 11% increase in sales, driven by healthy customer demand and improved business fundamentals.
- The company achieved a significant 24% increase in EBITDA, reaching a 12.3% EBITDA margin, marking a substantial improvement over the previous year.
- Operating cash flow improved significantly by almost 50%, reaching nearly $700 million in the fourth quarter, allowing for substantial debt reduction.
- The acquisition of Bonsai Lab contributed positively to growth, with strong margins and successful integration into the lab tech segment.
- AddLife AB (FRA:1AD1) is well-positioned to benefit from emerging technology trends such as next-generation sequencing, robotic surgery, and artificial intelligence, which are expected to drive future growth.
- The company faced a negative impact on financial net due to currency fluctuations, with a loss this year compared to a gain last year.
- There was a slight weakness in the academic research field, although it showed some improvement in the fourth quarter.
- Patient waiting lists did not decrease in the fourth quarter, which could delay potential positive impacts on surgical procedure demand.
- The company experienced a decrease in the number of employees, partly due to the winding down of certain operations, which may affect operational capacity.
- Despite improvements, the company's EBITDA growth of 14% was slightly below its financial target of 15%, indicating room for further improvement.
Good morning and welcome everyone to the AddLife AB 4th quarter presentation and we will take you through today and an overview of the quarter and the outlook for the future. And then after, of course, the presentation we will have a Q&A session, but as usual we have recorded a great video of a of a company within the group and this this time around it's triola so I encourage you all to stay home to watch that video of a fantastic company within the lab tech business area.
AddLife was able to finish 2024 in a very strong way. The company performed really well, driven by healthy customer demand, but also diligent work on the business fundamentals, improving efficiency and profitability continuously, and this is again an important piece of the ad life DNA.
Sales increased by 11%, quite healthy development, organic and currency adjusted the growth was 9%. In lab tech we saw strong instrument sales after a bit of a weakness in Q3 2024 and also a very healthy invoicing and sales development in Eastern Europe. On the medtech
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
